Curated news and analysis on clinical trials, drug approvals, and medical research.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
The FDA issued a Complete Response Letter for Atara Biotherapeutics' Ebvallo application, reversing its prior acceptance of the ALLELE trial design. Partner Pierre Fabre Pharmaceuticals has requested a Type A meeting to address the agency's concerns.
The AI in genomics market is estimated to grow from USD 1.97 billion in 2026 to USD 317.4 billion by 2040, while the drug discovery informatics market is expected to reach USD 11.18 billion by 2035, driven by machine learning integration and big data analytics.
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
The FDA informed uniQure that Phase 1/2 study data for AMT-130 in Huntington's disease is insufficient to support a biologics license application, recommending a prospective, randomized, double-blind, sham surgery-controlled study instead.
Systematic review identifies shared molecular signatures in brain and blood for major depressive disorder, while separate study finds brain-enriched circRNA can predict SSRI treatment response.
New research shows 73% of AI users in clinical trials report the technology met or exceeded expectations, with 70% confirming improvements in data accuracy and 93% of organizations already using or investigating AI applications.
Sanofi's oral BTK inhibitor rilzabrutinib received orphan drug designation in Japan for IgG4-related disease and warm autoimmune hemolytic anemia, while also securing U.S. FDA breakthrough therapy designation for the rare anemia indication.
A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.
Acurx Pharmaceuticals will discuss full year and fourth quarter 2025 financial results on March 13, 2026, and provide updates on ibezapolstat, its lead antibiotic candidate preparing for international Phase 3 trials for C. difficile infection.
New initiatives aim to address social determinants of health in oncology, while research reveals persistent disparities in treatment access and clinical trial participation for Black and minority cancer patients.
Charles River Laboratories forecasts 2026 adjusted earnings of $10.70-$11.20 per share, exceeding Wall Street expectations, as biotech demand for drug research services recovers and contract cancellations decline.
New research reveals that over a quarter of healthy years lost to breast cancer are linked to modifiable lifestyle factors, while scientists advance targeted therapies and identify cellular mechanisms behind postpartum breast cancer risk.
A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.
uniQure reports Q4 2025 results as investors await clarity on AMT-130 Huntington's disease gene therapy following FDA's November indication that Phase I/II data unlikely to support biologics license application.
Women with endometriosis face increased long-term risk for thyroid disorders including hypothyroidism and Graves disease, according to a 20-year retrospective study. ACOG released new clinical guidance aimed at reducing diagnostic delays through clinical diagnosis and earlier treatment initiation.
Actor James Van Der Beek died at age 48 from colorectal cancer, highlighting a troubling trend of rising cancer rates and deaths among younger Americans despite overall declines in older populations.
Xbrane Biopharma reported full year 2025 revenue of SEK 152.4 million and a profit of SEK 127.2 million, driven by a SEK 168.9 million gain from the Alvotech transaction. The FDA issued a Complete Response Letter for the company's ranibizumab biosimilar application in October.
New research warns AI pathology systems may use statistical shortcuts rather than biological signals, while a clinical trial shows stereotactic radiation improves quality of life for patients with multiple brain metastases compared to whole brain radiation.
